Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatments being developed for Covid-19 are expected to have better therapeutic effects than cytokine-specific therapies such as interleukin (IL)-6 and IL-1 inhibitors.
These antibodies target an earlier point in the inflammation pathway than inhibitors that target cytokines like IL-6 and IL-1. Therefore, they could have a broader and better therapeutic response. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
